How Elevance Health’s (ELV) Expansion and Earnings Pressures Have Changed Its Investment Story

• In the past week, Elevance Health announced its ongoing transformation into a broader healthcare solutions provider, expanding into primary care, digital health, and pharmacy services while reporting an 11% annual increase in Medicare Advantage memberships and a 5.2% rise in individual memberships for Q2 2025.
• At the same time, the company lowered its full-year adjusted earnings forecast due to pressures from changes in ACA and Medicaid markets, despite continued strength in its Medicare Advantage portfolio and specialty services expansion.
• We’ll now explore how Elevance Health’s enhanced focus on digital health and core earnings pressures might influence the company’s investment outlook.

The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

Elevance Health Investment Narrative Recap

To be a shareholder in Elevance Health, you need to believe that expanding beyond traditional insurance into digital health, primary care, and pharmacy services will unlock stronger earnings growth, even as short-term margin pressures emerge from ACA and Medicaid market shifts. The recent update reinforces this shift, but ongoing margin pressure from undercompensated risk in government-backed programs remains the most pressing challenge, while membership growth in Medicare Advantage continues to be a critical catalyst. Overall, while the news clearly confirms membership strength, it does not materially alter the most important near-term catalyst or risk profile for the business.

Among recent company announcements, Elevance Health’s new partnership with the Digital Medicine Society stands out and directly relates to its move into digital health solutions. This initiative highlights the company’s push to enhance digital product evaluation and integration, supporting operational efficiency gains that are especially relevant as Elevance aims to improve cost management and contain benefit expense ratios amid volatile medical trends.

Yet, despite these growth ambitions, investors should be mindful that persistent pressures in ACA and Medicaid could mean slower-than-expected margin recovery if...

Read the full narrative on Elevance Health (it's free!)

Elevance Health is projected to reach $230.4 billion in revenue and $7.4 billion in earnings by 2028. This outlook is based on a 6.8% annual revenue growth rate and a $2.0 billion increase in earnings from the current $5.4 billion level.

Uncover how Elevance Health's forecasts yield a $368.44 fair value, a 16% upside to its current price.

Exploring Other Perspectives

Fair value opinions from the Simply Wall St Community range from US$300 to US$1,503, based on 13 individual estimates. As many weigh the risks of ongoing margin compression in ACA and Medicaid, explore how your view compares with this wide spectrum of outlooks.

Explore 13 other fair value estimates on Elevance Health - why the stock might be worth over 4x more than the current price!

Build Your Own Elevance Health Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Elevance Health research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Elevance Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Elevance Health's overall financial health at a glance.

Want Some Alternatives?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Rare earth metals are the new gold rush. Find out which 29 stocks are leading the charge.
• Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.
• We've found 20 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com